Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 3
2006 3
2007 1
2008 6
2009 2
2010 5
2011 6
2012 4
2013 9
2014 16
2015 10
2016 10
2017 16
2018 22
2019 22
2020 24
2021 30
2022 36
2023 36
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

235 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
An updated review of the immunological mechanisms of keloid scars.
Lee CC, Tsai CH, Chen CH, Yeh YC, Chung WH, Chen CB. Lee CC, et al. Among authors: chung wh. Front Immunol. 2023 Mar 22;14:1117630. doi: 10.3389/fimmu.2023.1117630. eCollection 2023. Front Immunol. 2023. PMID: 37033989 Free PMC article. Review.
Ligelizumab for Chronic Spontaneous Urticaria.
Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, Bernstein JA, Brehler R, Chu CY, Chung WH, Danilycheva I, Grattan C, Hébert J, Katelaris C, Makris M, Meshkova R, Savic S, Sinclair R, Sitz K, Staubach P, Wedi B, Löffler J, Barve A, Kobayashi K, Hua E, Severin T, Janocha R. Maurer M, et al. Among authors: chung wh. N Engl J Med. 2019 Oct 3;381(14):1321-1332. doi: 10.1056/NEJMoa1900408. N Engl J Med. 2019. PMID: 31577874 Free article. Clinical Trial.
Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.
Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, Chang CJ, Su SC, Hui RC, Chin SW, Huang LF, Lin YY, Chang WY, Fan WL, Yang CY, Ho JC, Chang YC, Lu CW, Chung WH; the Taiwan Severe Cutaneous Adverse Reaction (TSCAR) Consortium. Wang CW, et al. Among authors: chung wh. J Clin Invest. 2018 Mar 1;128(3):985-996. doi: 10.1172/JCI93349. Epub 2018 Feb 5. J Clin Invest. 2018. PMID: 29400697 Free PMC article. Clinical Trial.
Updates in SJS/TEN: collaboration, innovation, and community.
Marks ME, Botta RK, Abe R, Beachkofsky TM, Boothman I, Carleton BC, Chung WH, Cibotti RR, Dodiuk-Gad RP, Grimstein C, Hasegawa A, Hoofnagle JH, Hung SI, Kaffenberger B, Kroshinsky D, Lehloenya RJ, Martin-Pozo M, Micheletti RG, Mockenhaupt M, Nagao K, Pakala S, Palubinsky A, Pasieka HB, Peter J, Pirmohamed M, Reyes M, Saeed HN, Shupp J, Sukasem C, Syu JY, Ueta M, Zhou L, Chang WC, Becker P, Bellon T, Bonnet K, Cavalleri G, Chodosh J, Dewan AK, Dominguez A, Dong X, Ezhkova E, Fuchs E, Goldman J, Himed S, Mallal S, Markova A, McCawley K, Norton AE, Ostrov D, Phan M, Sanford A, Schlundt D, Schneider D, Shear N, Shinkai K, Tkaczyk E, Trubiano JA, Volpi S, Bouchard CS, Divito SJ, Phillips EJ. Marks ME, et al. Among authors: chung wh. Front Med (Lausanne). 2023 Oct 11;10:1213889. doi: 10.3389/fmed.2023.1213889. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37901413 Free PMC article. Review.
New Advances in Drug Hypersensitivity Research and Treatment.
Tsai YG, Chung WH, Abe R, Tassaneeyakul W. Tsai YG, et al. Among authors: chung wh. J Immunol Res. 2018 Jun 21;2018:9345078. doi: 10.1155/2018/9345078. eCollection 2018. J Immunol Res. 2018. PMID: 30035134 Free PMC article. No abstract available.
235 results